Cargando…
Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience
PURPOSE: To assess the outcome and response of transcutaneous retrobulbar injection of amphotericin B (TRAMB) in post-coronavirus disease of 2019 (COVID-19) rhino-orbito-cerebral mucormycosis (ROCM) and to establish a scoring system in guiding treatment modalities. METHODS: An interventional, prospe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114606/ https://www.ncbi.nlm.nih.gov/pubmed/35225564 http://dx.doi.org/10.4103/ijo.IJO_2356_21 |
_version_ | 1784709815546675200 |
---|---|
author | Ramamurthy, Lakshmi B Bhandari, Ridhi Kanakpur, Savitha Thejaswini, P |
author_facet | Ramamurthy, Lakshmi B Bhandari, Ridhi Kanakpur, Savitha Thejaswini, P |
author_sort | Ramamurthy, Lakshmi B |
collection | PubMed |
description | PURPOSE: To assess the outcome and response of transcutaneous retrobulbar injection of amphotericin B (TRAMB) in post-coronavirus disease of 2019 (COVID-19) rhino-orbito-cerebral mucormycosis (ROCM) and to establish a scoring system in guiding treatment modalities. METHODS: An interventional, prospective study was done on 82 eyes of post-COVID-19 ROCM from May 2021 to July 2021. A comprehensive multi-departmental evaluation along with detailed ophthalmic examination, laboratory investigations, and radiological examination was done. Scoring points were given to each symptom, sign, and radiological features of orbit and the total score was taken. Based on these scores, severity of disease was grouped into A, B, and C corresponding to mild, moderate, and severe orbital ROCM. One milliliter of reconstituted liposomal amphotericin B was given to all patients every alternate day as three doses. Efficacy of these injections was assessed in all groups, even though other treatment modalities like orbital debridement and exenteration were considered for moderate and severe cases. Patients were followed up for a period of 8 weeks. RESULTS: Out of 82 eyes, symptomatic improvement was seen in a major proportion (72%) of patients. A statistically significant improvement in scores was noted in group A (93% improved) with a P value of 0.002, while 68.4% showed improvement in group B (P-value- 0.0001). Group C with severe disease showed minimal improvement in post-injection scores of 41% (P-value 0.086), necessitating surgical intervention. No serious adverse effect of the drug or procedure was noted. CONCLUSION: Significant improvement in scores of groups A and B highlights TRAMB as an effective and safe treatment modality in mild to moderate ROCM. It is an effective adjunct in severe cases, along with other interventions. Also, the scoring system helps in assessing the severity and guiding in management strategies. |
format | Online Article Text |
id | pubmed-9114606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-91146062022-05-19 Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience Ramamurthy, Lakshmi B Bhandari, Ridhi Kanakpur, Savitha Thejaswini, P Indian J Ophthalmol Expedited Publications, Original Article PURPOSE: To assess the outcome and response of transcutaneous retrobulbar injection of amphotericin B (TRAMB) in post-coronavirus disease of 2019 (COVID-19) rhino-orbito-cerebral mucormycosis (ROCM) and to establish a scoring system in guiding treatment modalities. METHODS: An interventional, prospective study was done on 82 eyes of post-COVID-19 ROCM from May 2021 to July 2021. A comprehensive multi-departmental evaluation along with detailed ophthalmic examination, laboratory investigations, and radiological examination was done. Scoring points were given to each symptom, sign, and radiological features of orbit and the total score was taken. Based on these scores, severity of disease was grouped into A, B, and C corresponding to mild, moderate, and severe orbital ROCM. One milliliter of reconstituted liposomal amphotericin B was given to all patients every alternate day as three doses. Efficacy of these injections was assessed in all groups, even though other treatment modalities like orbital debridement and exenteration were considered for moderate and severe cases. Patients were followed up for a period of 8 weeks. RESULTS: Out of 82 eyes, symptomatic improvement was seen in a major proportion (72%) of patients. A statistically significant improvement in scores was noted in group A (93% improved) with a P value of 0.002, while 68.4% showed improvement in group B (P-value- 0.0001). Group C with severe disease showed minimal improvement in post-injection scores of 41% (P-value 0.086), necessitating surgical intervention. No serious adverse effect of the drug or procedure was noted. CONCLUSION: Significant improvement in scores of groups A and B highlights TRAMB as an effective and safe treatment modality in mild to moderate ROCM. It is an effective adjunct in severe cases, along with other interventions. Also, the scoring system helps in assessing the severity and guiding in management strategies. Wolters Kluwer - Medknow 2022-03 2022-02-25 /pmc/articles/PMC9114606/ /pubmed/35225564 http://dx.doi.org/10.4103/ijo.IJO_2356_21 Text en Copyright: © 2022 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Expedited Publications, Original Article Ramamurthy, Lakshmi B Bhandari, Ridhi Kanakpur, Savitha Thejaswini, P Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience |
title | Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience |
title_full | Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience |
title_fullStr | Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience |
title_full_unstemmed | Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience |
title_short | Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience |
title_sort | outcome of transcutaneous retrobulbar injection of liposomal amphotericin b in post-covid-19 rhino-orbito-cerebral mucormycosis: our experience |
topic | Expedited Publications, Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114606/ https://www.ncbi.nlm.nih.gov/pubmed/35225564 http://dx.doi.org/10.4103/ijo.IJO_2356_21 |
work_keys_str_mv | AT ramamurthylakshmib outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience AT bhandariridhi outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience AT kanakpursavitha outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience AT thejaswinip outcomeoftranscutaneousretrobulbarinjectionofliposomalamphotericinbinpostcovid19rhinoorbitocerebralmucormycosisourexperience |